NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
Arlo Technologies, Inc. (NYSE: ARLO)
Class Period: Investors who purchased shares pursuant and/or traceable to the Company's Registration Statement and
Prospectus issued in connection with the August 3, 2018 Initial Public Offering
Lead Plaintiff Deadline: March 25, 2019
Join the action: https://www.zlk.com/pslra-1/arlo-technologies-inc-loss-form?wire=3
The filed complaint alleges that the Registration Statement made materially false and/or misleading statements and/or failed to
disclose that: (i) there was a flaw and/or quality issue with Arlo’s newly designed battery for its Ultra camera systems; (ii) this
flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo’s Ultra product; (iii) such a shipping
delay endangered Arlo’s chances of launching the Ultra product in time for the crucial holiday season; (iv) such a shipping delay
would allow Arlo’s competitors to capitalize on the Ultra product’s missed launch, thereby increasing their own market share; (v)
Arlo’s consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware
updates; (vi) because of the foregoing, Arlo’s fourth quarter 2018 results and consumer base would be negatively impacted; and
(vii) as a result, Arlo’s Registration Statement was materially false and misleading at all relevant times.
To learn more about the Arlo Technologies, Inc. class action contact jlevi@levikorsinsky.com.
Immunomedics, Inc. (NASDAQ: IMMU)
Class Period: February 8, 2018 - January 18, 2019
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3
About the lawsuit: During the class period, Immunomedics, Inc. allegedly made materially false and/or misleading statements
and/or failed to disclose that: (i) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in
compliance with FDA requirements; (ii) the Company’s Quality Control Unit did not possess the authority to
investigate and correct critical FDA violations occurring at the Morris
Plains, New Jersey facility; (iii) the Company suffered a February 2018
data integrity breach at the Morris Plains, New Jersey facility which,
among other issues, included the backdating records and manipulation of bioburden samples; (iv) the
Company’s Chemistry, Manufacturing and Control data submitted in connection with its
BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the
Company’s public statements were materially false and misleading at all relevant times
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.
DBV Technologies S.A. (NASDAQ: DBVT)
Class Period: February 14, 2018 - December 19, 2018
Lead Plaintiff Deadline: March 18, 2019
Join the action: https://www.zlk.com/pslra-1/dbv-technologies-s-a-loss-form?wire=3
About the lawsuit: DBV Technologies S.A. allegedly made materially false and/or misleading statements and/or failed to disclose
that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data
on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin
Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially
false and/or misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the DBV Technologies S.A. class action contact jlevi@levikorsinsky.com.
Yangtze River Port and Logistics Limited (NASDAQGS: YRIV)
Class Period: February 2, 2016 - December 5, 2018
Lead Plaintiff Deadline: March 4, 2019
Join the action: https://www.zlk.com/pslra-1/yangtze-river-port-and-logistics-ltd-loss-form?wire=3
About the lawsuit: Throughout the class period, Yangtze River Port and Logistics Limited allegedly made materially false and/or
misleading statements and/or failed to disclose that: (1) Yangtze’s purported lease of the Wuhan Yangtze River Newport
Logistics Center, the Company’s main asset, was a fabrication; (2) Yangtze’s only operating subsidiary, Wuhan Newport, was
declared insolvent in China due to a number of default judgments against it; and (3) as a result, Defendants’ statements
about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all
relevant times.
To learn more about the Yangtze River Port and Logistics Limited class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
